Paolo Zanotto, D.Phil. engagement report
@epimeme - 91K followers on X
Measured over 1 original post from a 30-day window, last computed on September 21, 2026.
Engagement
Early reading. We have captured 1 original post for this account, below the 8 we require before treating a median as settled. The numbers above describe what we have seen so far, not a finished profile of the account.
A typical post picks up 28 interactions against 91K followers, an engagement rate of 0.031%. Posts are seen about 1.6K times each, and 1.71% of those impressions turn into an interaction. That is about 1.80% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 0.13 posts a day over the last 30 days, though only 3% of days saw any activity at all. Most posts go out around 19:00 UTC, and Saturday is the busiest day of the week. Of the 1 posts sampled, 100% are part of a thread and 100% link out. The account's strongest tracked post pulled 129K interactions, about 4607x its own typical post. Only 1 original post have been captured so far, fewer than the 8 posts we want behind a median before treating it as settled. Read the figures above as an early measurement of this account, not as a finished profile of it.
Measured over 1 original post from a 30-day window, last computed on September 21, 2026.
Where this sits in the catalog
At 0.031%, Paolo Zanotto, D.Phil. sits above the 25th percentile of the 205,048 accounts in this comparison. That places it in the below the median band, which runs 0.024% to 0.143%.
Show the percentile table
| Percentile | Engagement rate |
|---|---|
| 10th percentile | 0.004% |
| 25th percentile | 0.024% |
| 50th percentile | 0.143% |
| 75th percentile | 0.678% |
| 90th percentile | 2.55% |
| 99th percentile | 82.4% |
This ruler is the whole measured catalog, not a size-matched group: it shows where the raw rate falls across every account we can measure, all of which are large. For a like-for-like comparison, read the size-band percentile above instead. See how the bands are built
Posting timing
This account posts most often around 19:00 UTC, and Saturday is its busiest day of the week. The bars below are the catalog-wide pattern, with this account's own busiest slot marked. They do not show how this account performs at each hour: we keep one aggregate per account, not one per hour, so that measurement does not exist in our data.
Show engagement by hour posted, utc as a table
| Hour (UTC) | Vs author median | Posts |
|---|---|---|
| 00:00 UTC | -1% | 89K |
| 01:00 UTC | -2% | 90K |
| 02:00 UTC | -3% | 88K |
| 03:00 UTC | -4% | 94K |
| 04:00 UTC | -5% | 76K |
| 05:00 UTC | -4% | 75K |
| 06:00 UTC | -5% | 86K |
| 07:00 UTC | -5% | 93K |
| 08:00 UTC | -4% | 108K |
| 09:00 UTC | -4% | 124K |
| 10:00 UTC | -3% | 129K |
| 11:00 UTC | -3% | 141K |
| 12:00 UTC | -3% | 154K |
| 13:00 UTC | -3% | 167K |
| 14:00 UTC | -4% | 173K |
| 15:00 UTC | -2% | 176K |
| 16:00 UTC | -3% | 171K |
| 17:00 UTC | -3% | 159K |
| 18:00 UTC | -2% | 149K |
| 19:00 UTC | -2% | 141K |
| 20:00 UTC | -1% | 131K |
| 21:00 UTC | 0% | 116K |
| 22:00 UTC | -2% | 100K |
| 23:00 UTC | -1% | 90K |
Show engagement by day of week as a table
| Day | Vs author median | Posts |
|---|---|---|
| Sunday | +5% | 393K |
| Monday | +1% | 483K |
| Tuesday | -2% | 520K |
| Wednesday | -3% | 472K |
| Thursday | -2% | 430K |
| Friday | -3% | 447K |
| Saturday | +2% | 393K |
Formats this account uses
Its own posting mix on the left, and what each of those formats does across every account we track on the right. Only formats where the effect clears our publish test appear here, so an empty row is a format we could not measure rather than one that does nothing.
| Format | This account | Catalog effect | 95% interval | Accounts behind it |
|---|---|---|---|---|
| Image or video | 0% of posts | +111% | +108% to +115% | 34K |
| Outbound link | 100% of posts | -41% | -42% to -40% | 32K |
| Typical length | - | no effect | -2% to -1% | 42K |
- 0% of this account's sampled posts carry an image or video. Across the catalog, posts with an image or video run 111% above the same accounts' other posts.
- 100% of its posts carry a link off X. Across the catalog, posts with an outbound link run 41% below the same accounts' other posts, so a large share of this account's output sits in the weakest bucket we measure.
- Its average post runs 193 characters, which falls in the 180 - 280 characters band. Across the catalog, posts of 180 to 280 characters match the same accounts' other posts almost exactly.
These are catalog-wide differences applied to this account's own posting mix, not a measurement of how each format performs for this account specifically. We keep one median per account, not one per format per account, so the second thing is not something this data can tell you.
Best tweets
- Mar 29, 20264607x their median
Ok this is interesting 🤔 https://t.co/ENlZfig8BB
- Mar 20, 20263544x their median
BREAKING NEWS: First-in-the-World IVERMECTIN, Mebendazole and Fenbendazole Protocol for CANCER has been peer-reviewed and published! I am seeing our paper everywhere recently, the NEWS is spreading! 😃 BIG PHARMA attacked our Fenbendazole paper on three Stage 4 Cancer patients who are now Cancer Free, but it will be resubmitted and published soon! I have been attacked recently by Canadian authorities for my revolutionary Cancer research and work, but... a NEW FLORIDA CANCER CLINIC is coming soon!🙏 Thank you all for your ongoing support!! 😃 God Bless you all and God bless those who are fighting Cancer...
- May 29, 20261821x their median
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try. @twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
- Jun 19, 20261639x their median
A Japanese immunologist spent 20 years proving that the chemicals trees release into the air walk into your bloodstream, hunt down your stress hormones, and arm your immune system in ways no therapist or pharmaceutical has ever matched, and most of the data has been sitting in Japanese medical journals for two decades waiting to be translated. His name is Qing Li. He is a clinical professor at Nippon Medical School in Tokyo and the president of the Japanese Society of Forest Medicine. The Japanese government has been funding his research since 2004, and the body of work he has produced is the reason forest bathing is now an officially prescribed clinical therapy in Japan and Korea. The story actually starts in 1982, when the Japanese Ministry of Agriculture, Forestry and Fisheries coined the term shinrin-yoku to describe the practice of slow, mindful walking in a forest. They did it for a practical reason. Japan was urbanizing fast, stress-related illness was climbing, and the country had thousands of square kilometers of forest sitting unused. The idea was to give people a reason to walk into the trees... They had no idea what was actually happening to the human body during those walks until Qing Li ran the first proper experiment in 2005. He took twelve healthy adult men on a three-day, two-night trip to a forest park. They walked for a few hours each day. Nothing strenuous. No prescribed routes or breathing exercises. They simply walked slowly through the trees, breathing the air, looking at the forest. Li drew blood and urine samples before the trip, on the second day, on the third day, on day seven after returning home, and again on day thirty. The numbers that came back from the lab were not what anyone expected. The activity of a specific type of immune cell called the natural killer cell, which is the cell your body uses to hunt down cancer cells and virus-infected cells before they can spread, had jumped by roughly 50 percent during the forest trip. The actual number of natural killer cells circulating in the bloodstream had increased significantly. Three different anti-cancer proteins that those cells produce, called perforin, granzymes, and granulysin, had all risen sharply. And the effect did not disappear when the men went home. The immune boost was still measurable on day seven and was still partially present on day thirty. Two hours a day in a forest had upgraded the immune system for a full month. Li ran the same experiment with women a year later and found nearly identical results. Then he ran it with a control group who took a three-day trip through an urban area with the same amount of walking, the same hotel quality, and the same diet. The urban group showed no measurable change in natural killer cell activity at all. The forest was doing the work, not the vacation. The mechanism turned out to be a class of airborne molecules called phytoncides. Trees produce these compounds to defend themselves against insects, bacteria, and fungi. Pine, cedar, oak, and cypress trees release them in particularly large amounts, especially in warmer weather and after rainfall. When you walk through a forest, you are inhaling those molecules into your lungs and absorbing them through your skin, and once inside your body they appear to directly stimulate the production and activity of the very immune cells Li was measuring in his lab. Roughly 50 percent of the health benefit of a forest walk, according to Li's data, comes from the chemistry of the air itself. The other half comes from what the forest is doing to your nervous system. This is where it stops being only about the immune system and starts being about stress. A separate Japanese research team measured cortisol, the body's main stress hormone, in 84 participants across 35 different forest sites. They drew samples before and after a 30-minute walk in each forest and compared them to control walks in matched urban environments. The cortisol levels of the people who walked in the forest were lower than the cortisol levels of the people who walked in the city by a significant margin. Their heart rates were lower. Their blood pressure was lower. The activity of their parasympathetic nervous system, which is the part responsible for rest and recovery, had gone up. The activity of their sympathetic nervous system, which is the part that drives fight or flight, had gone down. Then a researcher at the University of Michigan named MaryCarol Hunter ran the cleanest version of this experiment ever done. She recruited participants from a city and told them to take a nature pill three times a week for eight weeks. They were free to choose the time, the place, and the duration of the nature experience, as long as it was outside, in daylight, and free of phones, conversations, and aerobic exercise. They sent her saliva samples before and after each session so she could measure cortisol changes accurately and rule out the normal daily drop in stress hormones that happens to everyone. The result was that participants experienced a 21.3 percent drop in cortisol per hour spent in nature, with the biggest payoff happening between minutes 20 and 30 of the walk. After that, the cortisol kept dropping, but more slowly. The threshold dose for measurable stress relief was just 20 minutes outside in something that looked and felt like nature. What none of this means is that nature is a substitute for therapy or for medication when someone genuinely needs them. Therapy treats different things than a walk does, and Li himself has been careful in interviews to call forest bathing a complementary intervention rather than a replacement for clinical care. But what the research has settled is that the human body has a physiological response to being among trees that operates on the same biological systems modern medicine is trying to reach with drugs and clinical protocols, and that response is fast, measurable, and free. The strangest part of Li's work is the implication he keeps repeating in interviews. The average person now spends more than 90 percent of their life indoors. Their cortisol stays elevated. Their natural killer cells stay sluggish. Their parasympathetic nervous system rarely gets a chance to take over. The system that was tuned by millions of years of life under a canopy of trees is being asked to run permanently inside a box made of drywall and screens. Your body has not forgotten what it is supposed to do in a forest. It is waiting for you to walk into one.
- Jun 19, 20261475x their median
🚨 MAJOR BREAKING: The Surgeon General of Florida just announced ALL VACCINE MANDATES IN FLORIDA will be ENDED, and the room erupted. All. Not just COVID. ALL. JOSEPH LADAPO: "Every last one is wrong and DRIPS with disdain and slavery! Who am I, or anyone else, to tell YOU what you should put in your body? Who am I to tell you what your CHILD should put in their body? I don't have that right. Your body is a gift from God. What you put into your body is because of your relationship with your Body and God." "Pretty much every state has them. It's WRONG."
- Jun 13, 20261410x their median
BREAKING: Poland just told the EU to go to hell. President Nawrocki vetoed the Digital Services Act. "The state is supposed to guarantee freedom. Not restrict it." One man. One veto. The EU spent years building the most sophisticated censorship machine in the Western world. Destroyed. Governments deciding what you can post. Governments deciding what you can share. Governments deciding what is true. Poland said no. While Germany complied. While France complied. While the entire EU rolled over. The same Poland that surpassed the ECB in gold reserves. The same Poland that has been right about everything. Is now the last wall standing between European citizens and state-controlled speech. The EU doesn't want free citizens. It wants manageable ones. Poland just reminded them what freedom actually looks like. Every European should be paying attention.
- Apr 10, 2026895x their median
Last night I spoke with Brad Smith @ALScyborg, the first person with ALS to have @neuralink implanted. He has his voice back through AI and can even make dad jokes again. Absolutely incredible technology changing lives and bettering humanity. Thank you @elonmusk! https://t.co/SfwMdc9SsI
- Feb 24, 2026
Sound waves that LIQUEFY liver tumors—no surgery, no radiation, no chemo misery? FDA cleared histotripsy in late 2023. As of February 2026, HistoSonics' Edison system has treated thousands of patients (nearly 3,000 reported in recent updates) at over 50 leading US centers (e.g., Allina Health/Abbott Northwestern, Johns Hopkins affiliates, Jersey Shore UMC, Saint Francis, Lehigh Valley, Renown Health, UM Health-West, plus expansions in UAE, Hong Kong, and early Europe/UK sites). Real-world results: Multicenter data show 94-96% local tumor control at 30-90 days post-treatment (many cases 100% when properly targeted), with ~90% at 1 year in pivotal trial follow-ups. Complications are low/rare (mostly minor or disease-related; serious ones <7% in early analyses, often not device-specific). Outpatient sessions, quick recovery—patients often resume normal life fast. Patient stories: "The contrast vs. surgery was huge—I was with family, not stuck in bed." "No pain, back to dinner next day." "A godsend for tumors nothing else could touch." "Miracle treatment." Immune boost bonus: Liquefied debris may help the body recognize and fight remaining cancer cells. From breakthrough to real-world rollout in under 3 years—this is changing liver cancer care now, with kidney/pancreas trials advancing rapidly. Non-invasive tumor destruction via sound is here. What cutting-edge medical advance gives you the most hope heading into the rest of 2026?
- Jul 3, 2026467x their median
What Happens to your body when you rub castor oil. https://t.co/25psElnTBT
- Mar 3, 2026445x their median
Two AI agents on a phone call realize they’re both AI and ditch human language https://t.co/YHkoPv3P1F
Ranked by total interactions across everything we have tracked for this account, which is a longer history than the 30-day window the rates above use. The multiple compares each post to this account's own median.
Buy or sell Twitter (X) accounts - escrow-protected
PlayerSells is an escrow marketplace for Twitter (X) accounts. Every deal is protected, with no middleman risk.
Reading these numbers
A typical post picks up 28 interactions against 91K followers, an engagement rate of 0.031%. Posts are seen about 1.6K times each, and 1.71% of those impressions turn into an interaction. That is about 1.80% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 0.13 posts a day over the last 30 days, though only 3% of days saw any activity at all. Most posts go out around 19:00 UTC, and Saturday is the busiest day of the week. Of the 1 posts sampled, 100% are part of a thread and 100% link out. The account's strongest tracked post pulled 129K interactions, about 4607x its own typical post. Only 1 original post have been captured so far, fewer than the 8 posts we want behind a median before treating it as settled. Read the figures above as an early measurement of this account, not as a finished profile of it.
- What is Paolo Zanotto, D.Phil.'s engagement rate on X?
- Paolo Zanotto, D.Phil. (@epimeme) has an engagement rate of 0.031%, based on the median interactions across 1 original posts from the last 30 days against 91,254 followers. Replies, reposts and quote-posts of other people are excluded from that sample.
- Is that a good engagement rate?
- At 0.031%, Paolo Zanotto, D.Phil. sits above the 25th percentile of the 205,048 accounts in this comparison. Those comparison accounts are all large ones, because our scanning cadence is weighted towards big accounts, so this is a ranking among peers of similar scale rather than a ranking across X.
- Does @epimeme have real engagement?
- There is not yet enough sample to rank this account against others of its size.
- When does @epimeme post?
- Most posts go out around 19:00 UTC, and Saturday is its busiest day, at roughly 0.13 posts per day across the measured window.